While MEK inhibitor monotherapy is mainly associated with retinal and choroidal abnormalities, but also with diffuse abnormalities and panuveitis, B-Raf inhibitor monotherapy is significantly associated with iris and ciliary body abnormalities, diffuse abnormalities, and anterior uveitis and panuveitis. This evidence concerns the gene MAP2K7 and panuveitis.